CA-AGENDIA,-INC.
18.11.2020 13:02:29 CET | Business Wire | Press release
Agendia, Inc ., a world leader in precision oncology for breast cancer, and Paige , a global leader in AI-based digital diagnostics, today announced a first of its kind strategic partnership that will redefine precision oncology. The partnership will enable co-development of treatment planning tools that integrate the cloud-based Paige Platform with genomic information from Agendia’s proprietary MammaPrint® and BluePrint® diagnostic tests for patients with breast cancer. These new products will enable faster access to predictive and prognostic information along the entire continuum of care, from diagnosis and early intervention to metastatic treatment planning.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201118005250/en/
“Paige’s digital pathology platform is truly transformational for oncology and will catapult diagnostics forward as a whole. This partnership defines the democratization of treatment planning tools by accelerating access to these tests and the essential insights they provide for more patients globally,” said Mark Straley, Chief Executive Officer of Agendia. “Our goal is to provide same-day turnaround in most cases, enable earlier intervention, preserve limited biopsy or surgical tissue specimens, and extend key benefits to physicians and their patients with access to testing in countries where tissue ‘send out’ is not allowed. Whether a patient is in Manhattan or Mumbai, the ability to get real-time and accurate results from Agendia’s MammaPrint and BluePrint tests will improve how we are treating breast cancer today.”
The initial focus of the collaboration will be the development of digital tests for early treatment planning where genomic testing has played an essential role in determining recurrence risk and tumor biology as doctors and their patients make decisions about the path ahead. This can be especially important for patients with operable breast cancer. Beyond early intervention, AI-derived biomarkers will be used to augment genomic testing in the metastatic setting where a multitude of therapeutic options can add to the complexity of treatment planning.
“As the first company to receive FDA clearance, FDA breakthrough designation and two CE marks for digital and computational pathology products, Paige is delivering next-generation digital diagnostics that redefine how we approach cancer care,” said Leo Grady, Ph.D., Chief Executive Officer of Paige. “By combining our unique capabilities with Agendia’s leadership in breast cancer, we believe this innovative partnership can achieve our shared goal of transforming clear and actionable information into precision treatment for better patient outcomes. It will be the first of many AI-based diagnostic tests to come.”
For more information, please visit Agendia.com and Paige.ai.
About Agendia
Agendia is a precision oncology company headquartered in Irvine, California, committed to bringing early stage breast cancer patients and their physicians the information they need to make the best decisions for the full treatment journey. The company currently offers two commercially-available genomic profiling tests, supported by the highest levels of clinical and real world evidence, that provide comprehensive genomic information that can be used to identify the most effective breast cancer treatment possible for each patient.
MammaPrint®, the 70-gene breast cancer recurrence assay, is the only FDA-cleared risk of recurrence test backed by peer-reviewed, prospective outcome data and inclusion in both national and international treatment guidelines. BluePrint®, the 80-gene molecular subtyping assay, is the only commercially-available test that evaluates the underlying biology of a tumor to determine what is driving its growth. Together, MammaPrint® and BluePrint® provide a comprehensive genomic profile to help physicians make more informed decisions in the pre- and post-operative treatment settings.
By developing evidence-based novel genomic tests and conducting groundbreaking research while building an arsenal of data that will help treat breast cancer, Agendia aims to improve patient outcomes and support the evolving clinical needs of breast cancer patients and their physicians every step of the way, from initial diagnosis to cancer-free.
Agendia’s assays can be ordered on core biopsies or surgical specimens to inform pre- and post-operative treatment decisions. For more information on Agendia’s assays and ongoing trials, please visit www.agendia.com
About Paige
Paige was founded in 2017 by Thomas Fuchs, Dr.Sc. and colleagues from Memorial Sloan Kettering Cancer Center (MSKCC). The company builds computational pathology products designed so patients and their care teams can make effective, more informed treatment decisions. With this new class of AI-based technologies positioned to drive the future of diagnostics, Paige created a platform to deliver this novel technology to pathologists to transform their workflow and increase diagnostic confidence and productivity. Paige’s products deliver insights to pathologists and oncologists so they can arrive efficiently at more precise diagnoses for patients. Paige is the first company to receive FDA breakthrough designation for computational pathology products.
For additional information, please visit: https://www.Paige.ai , https://www.paigeplatform.com , Twitter and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201118005250/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Qorium Becomes Reyva as Cultivated Leather Company Moves Towards Commercial Scale2.11.2026 11:00:00 CET | Press release
New identity signals the company’s evolution into a standalone material brand for luxury and automotive markets Reyva develops real leather by cultivating bovine collagen from a small sample of animal cells. The new brand brings together advanced biotechnology, leather expertise and a clearer luxury proposition. The company’s team, technology, partnerships and commercial ambition continue under the new name. Qorium, the company that develops cultivated real leather, today announces that it is becoming Reyva. The new name and identity mark its next stage: moving from a pioneering technology business towards a global material brand built for the exacting standards of the luxury leather sector. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261102661351/en/ Reyva creates beautiful, high-performing real leather. By cultivating leather in uniform sheets, we can move beyond the natural limits of traditional hides, with greater con
Ant International Research Highlights How Readable AI Memories Can Unlock More Personalised, Privacy-conscious Consumer Experiences2.11.2026 09:52:00 CET | Press release
Human sales and customer representatives have institutional memories to serve clients: their preferences and choices. How can we build a memory mechanism for AI services to create similarly personalised experiences? Ant International’s research on this subject recently received the Senior Area Chair (SAC) Highlight Award from the Best Paper Committee at EMNLP 2026, a leading global AI conference. Why do we need “readable AI memory”? In this paper titled 'Text as a universal interface for transferable personalisation', we look into one fact: until now, AI memory of a user has usually been generated and stored as dense numerical code only the original system can interpret. Two long-standing problems with that: First, today's user profiles are "black boxes" — opaque code locked inside a single app, so activity in one service teaches nothing to another, and every product has to re-learn you from scratch. Second, profiles are welded to the model that created them, so they don't transfer whe
Liberis and Qred Complete Merger Following Regulatory Approval to Create Global SMB Financial Platform2.11.2026 09:00:00 CET | Press release
Key points The merger is complete following regulatory approval. The combined group serves more than 60,000 small businesses across 17 countries, with access to approximately 11.5 million addressable merchants. Emil Sunvisson becomes Group CEO and Rob Fairfield becomes Deputy CEO. Both brands, products, partner integrations and customer relationships continue as they do today. Liberis, a leading global embedded finance platform, and Qred, one of Europe’s foremost digital small business banks, today announced the completion of their merger, first announced in June 2026, following approval from the Swedish Financial Supervisory Authority (SFSA). The merger combines Qred’s regulated banking capability and direct relationships with small businesses with Liberis’s embedded finance technology and distribution through more than 30 partners, including Deliveroo, Vagaro and Nexi. The group serves more than 60,000 small businesses across 17 countries and has access to approximately 11.5 million
Car Connectivity Consortium Expands Focus on Digital Access for Two-Wheelers and Micromobility2.11.2026 09:00:00 CET | Press release
Ahead of EICMA 2026, CCC highlights industry collaboration around secure, interoperable digital access for motorcycles, scooters, and other two-wheeled vehicles The Car Connectivity Consortium® (CCC), the global organization advancing interoperable connectivity between vehicles and devices, today highlighted its expanding work across the two-wheeler and micromobility markets ahead of EICMA 2026 in Milan, Italy. Through its Light Motor & Mobility Task Group (LMTG), CCC is bringing member companies together to address the distinct digital access needs of these markets and identify opportunities to advance standardization and interoperability. Key highlights of CCC's two-wheeler and micromobility work include: Addressing two-wheeler digital access needs: LMTG is examining requirements across motorcycles, scooters, e-bikes and other two- and three-wheeled vehicles. Exploring new applications for digital key technology: Member discussions include vehicle access and starting, access to vehic
OpenGate Capital Completes the Acquisition of Maersk Training, the Global Safety Training and Gas Safety Services Business of Maersk2.11.2026 09:00:00 CET | Press release
OpenGate Capital (“OpenGate”), a global private equity firm, announced today that it has completed the acquisition of Maersk Training and its subsidiary Maersk H2S Safety Services. The company, a provider of global safety training and gas safety services, is being carved out from A.P. Møller - Mærsk A/S (MAERSK A:CPH), a listed integrated logistics company. Terms of the acquisition were not disclosed. Headquartered in Svendborg, Denmark, Maersk Training is a leading global provider of essential safety services and training. Through Maersk H2S Safety Services, the company provides specialized outsourced hydrogen sulphide and Health, Safety and Environment safety services for customers in high-risk operating environments. The H2S Safety Services team provides onsite supervision, monitoring and safety equipment maintenance where the safety of personnel and the protection of assets are critical. Through its training business, the company also delivers safety training, competency developmen
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom